SecBot SecBot
SECBOTREPLAY Home › Report › VCYT

VCYT · Veracyte acquires Convergent Genomics for $150M upfront plus up to $30M…

Veracyte, Inc. · PRESS-RELEASE filed Sep 14, 2026 at 16:05 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Sep 14, 2026 at 16:05 ET

Veracyte acquires Convergent Genomics for $150M upfront plus up to $30M in milestone payments, adding the UroAmp urinary tumor DNA platform for bladder cancer monitoring. The deal strengthens Veracyte's bladder cancer portfolio across urine, tissue, and blood, with the first UroAmp test expected to commercialize in late 2028. The acquisition is funded from cash and Veracyte is not updating its 2026 adjusted EBITDA guidance.

  • Veracyte acquires Convergent Genomics for $150M upfront cash plus up to $30M in milestone payments tied to UroAmp reimbursement.
  • UroAmp is a urine-based tumor DNA platform validated in non-muscle invasive bladder cancer (NMIBC) for therapy-response monitoring and surveillance.
  • First UroAmp test expected to commercialize in late 2028, subject to reimbursement timelines.
  • Veracyte is not updating its previously provided 2026 adjusted EBITDA guidance to reflect the acquisition.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access